Xanodyne Pharmaceuticals, a Newport, Ky., specialty-pharmaceutical company specializing in narcotic pain drugs and prenatal vitamins, raised $25 million in an extension of a 2005 recapitalization, VentureWire reports (subscription required). Investors included Blue Chip Venture, HealthCare Ventures, Essex Woodlands Health Ventures, MPM Capital, Apax Partners and Aisling Capital.

Xanodyne purchased the pharmaceuticals division of aaiPharma in 2005, and so now sells a variety of narcotic painkillers that include Darvon, Darvocet and forms of methadone, morphine and oxycodone, as well as its prenatal vitamins. The company told VentureWire it raised the funds to prepare for an IPO sometime in the next six to nine months.